My watch list
my.bionity.com  
Login  

21 Current news about the topic chronic myeloid leukemia

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Enzyme's movement may be key to new cancer drugs

17-May-2018

Revealing all the steps required to activate an enzyme called a protein kinase may identify new ways to target cancer, according to new University of Arizona-led research. Not only must the kinase have all needed parts in place, the enzyme must move in the correct manner and at the correct speed ...

more

New targets for approved cancer drug discovered

11-Oct-2017

Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently. A team of researchers at Moffitt Cancer ...

more

image description
Interaction between two leukemia drugs explained

07-Nov-2013

Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek’s group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang ...

more

High leukemia treatment costs may be harming patients

Increasing, unsustainable prices for leukemia drugs represent larger issue across all cancers

29-Apr-2013

The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more ...

more

Temple scientists target DNA repair to eradicate leukemia stem cells

12-Dec-2012

Despite treatment with imatinib, a drug that targets chronic myeloid leukemia (CML, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression ...

more

Novartis drug Tasigna recommended for approval in European Union for newly diagnosed Ph+ chronic myeloid leukemia

28-Sep-2010

Novartis has received a positive opinion recommending European Union approval of Tasigna® (nilotinib), a selective targeted therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The Committee for Medicinal Products ...

more

Novartis drug Tasigna approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML

31-Aug-2010

Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since ...

more

FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients

22-Jun-2010

Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. With this approval, Tasigna becomes the first new ...

more

Novartis drug Tasigna surpasses Glivec in slowing disease progression for newly diagnosed CML patients

04-Jun-2010

Novartis announced 18-month results (median follow-up) showing that Tasigna® (nilotinib) significantly surpasses Glivec® (imatinib) in slowing disease progression in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. This ...

more

Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia

Study results show Tasigna exceeds Glivecin every measure of efficacy in the trial including prevention of disease progression at 12 months

23-Feb-2010

Novartis announced that Tasigna (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is ...

more

Page 1 From 3
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE